These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 17539006

  • 1. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F, Camaggi V, Ravaioli M, Grazi GL, Zanello M, Leoni S, Ballardini G, Cavrini G, Pinna AD, Bolondi L.
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [Abstract] [Full Text] [Related]

  • 2. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH.
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [Abstract] [Full Text] [Related]

  • 3. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY, Bass NM, Ascher NL, Roberts JP.
    Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
    [Abstract] [Full Text] [Related]

  • 4. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
    Cuomo O, Perrella A, Arenga G.
    Transplant Proc; 2008 May; 40(6):1906-9. PubMed ID: 18675085
    [Abstract] [Full Text] [Related]

  • 5. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era.
    Ravaioli M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Zanello M, Ballardini G, Varotti G, Vetrone G, Tuci F, Lauro A, Ramacciato G, Pinna AD.
    Transplantation; 2006 Feb 27; 81(4):525-30. PubMed ID: 16495798
    [Abstract] [Full Text] [Related]

  • 6. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP.
    Liver Transpl; 2003 Jul 27; 9(7):684-92. PubMed ID: 12827553
    [Abstract] [Full Text] [Related]

  • 7. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus.
    Thuluvath PJ, Maheshwari A, Thuluvath NP, Nguyen GC, Segev DL.
    Liver Transpl; 2009 Jul 27; 15(7):754-62. PubMed ID: 19562709
    [Abstract] [Full Text] [Related]

  • 8. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD.
    Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M, Bak T, Kam I, Everson GT.
    Liver Transpl; 2004 Jan 27; 10(1):42-8. PubMed ID: 14755776
    [Abstract] [Full Text] [Related]

  • 9. Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY, Huo SC, Lee PC, Lee SD.
    Clin Transplant; 2008 Jan 27; 22(4):469-75. PubMed ID: 18318736
    [Abstract] [Full Text] [Related]

  • 10. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN, Perkins JD, Carithers RL.
    Gastroenterology; 2008 May 27; 134(5):1342-51. PubMed ID: 18471511
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
    Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA.
    Clin Transplant; 2012 May 27; 26(4):E359-64. PubMed ID: 22693962
    [Abstract] [Full Text] [Related]

  • 12. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization.
    Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G.
    Liver Transpl; 2004 Mar 27; 10(3):449-55. PubMed ID: 15004776
    [Abstract] [Full Text] [Related]

  • 13. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy.
    Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Huang YH, Lee PC, Chang FY, Lee SD.
    Liver Transpl; 2004 Dec 27; 10(12):1507-13. PubMed ID: 15558587
    [Abstract] [Full Text] [Related]

  • 14. Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans.
    Ahmad J, Downey KK, Akoad M, Cacciarelli TV.
    Liver Transpl; 2007 Nov 27; 13(11):1564-9. PubMed ID: 17969210
    [Abstract] [Full Text] [Related]

  • 15. Impact of model for end-stage liver disease on patient survival and disease-free survival in patients receiving liver transplantation for hepatocellular carcinoma.
    Moonka D, Castillo E, Kumer S, Abouljoud M, Divine G, Pelletier S.
    Transplant Proc; 2009 Nov 27; 41(1):216-8. PubMed ID: 19249517
    [Abstract] [Full Text] [Related]

  • 16. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM, ESLD-HIV Working Group Investigators.
    Liver Transpl; 2009 Sep 27; 15(9):1133-41. PubMed ID: 19718643
    [Abstract] [Full Text] [Related]

  • 17. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system.
    Adler M, De Pauw F, Vereerstraeten P, Fancello A, Lerut J, Starkel P, Van Vlierberghe H, Troisi R, Donckier V, Detry O, Delwaide J, Michielsen P, Chapelle T, Pirenne J, Nevens F.
    Liver Transpl; 2008 Apr 27; 14(4):526-33. PubMed ID: 18383082
    [Abstract] [Full Text] [Related]

  • 18. Model for End-Stage Liver Disease (MELD) score and organ allocation from cadaveric donors for 198 liver transplantation procedures performed in a single center.
    Santori G, Andorno E, Morelli N, Casaccia M, Bottino G, Ghirelli R, Valente U.
    Transplant Proc; 2008 Apr 27; 40(6):1903-5. PubMed ID: 18675084
    [Abstract] [Full Text] [Related]

  • 19. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement?
    Roayaie K, Feng S.
    Liver Transpl; 2007 Nov 27; 13(11 Suppl 2):S36-43. PubMed ID: 17969067
    [Abstract] [Full Text] [Related]

  • 20. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR, Ferguson N, Cannon RM, Jones CM, Brock GN.
    Liver Transpl; 2015 May 27; 21(5):612-22. PubMed ID: 25694099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.